Phase III trials are primarily designed to

• A. Phase III trials enroll participants in a single site.
• B. Phase III trials are primarily used to assess manufacturing quality.
• C. Phase III trials determine safety, efficacy and dose.
• D. Phase III trials occur after FDA approval to confirm labeling.

Answer: (C)

Phase III trials are designed to provide definitive evidence of a drug’s safety and effectiveness in a larger, more diverse patient population, and to establish the optimal dose for clinical use. These studies are typically randomized and controlled, often conducted across multiple centers, and they look at meaningful clinical outcomes to assess the benefit–risk profile. The data from Phase III trials support regulatory approval and help define labeling, including the approved dose.

Enrolling participants at a single site isn’t characteristic of Phase III, which usually involves many sites to reflect real-world use. Manufacturing quality is addressed mainly through other regulatory activities and ongoing controls (the chemistry, manufacturing, and controls aspect), not the primary aim of Phase III. And doing the trial after FDA approval to confirm labeling describes Phase IV, post-marketing studies, not Phase III.